ClinicalTrials.gg
Drug

Tivumecirnon clinical trials

Also written FLX475.

studies test it
3
open now
0
in phase 3
0
first study started
2018

How each study uses tivumecirnon has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

FLX475
2

Studies by the year they started

3 studies that test it; most in 2021 (2)

Studies that test tivumecirnon, by start year
YearStudies
20181
20212

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 0

RAPT Therapeutics, Inc. (2) · Hanmi Pharmaceutical Company Limited (1)

Studies

Open first, then newest update. How each study uses tivumecirnon has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Tested with established drugs · 3 — they are given beside it

Codes

What other systems call tivumecirnon · ClinicalTrials.gg INT017745

  • UNII (FDA) R1T69T65FJTIVUMECIRNONOne source FDA
  • NCI Thesaurus C157240TivumecirnonOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion